Lymphoma

A collection of features and news articles published in ASH Clinical News related to lymphoma.

FDA Approves Duvelisib for Patients with CLL or SLL

The U.S. Food and Drug Administration has approved the PI3K inhibitor duvelisib for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia...

FDA Approves Mogamulizumab-kpkc for Two Types of Non-Hodgkin Lymphoma

The U.S. Food and Drug Administration (FDA) approved mogamulizumab-kpkc for intravenous use in patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome...

Can a Liquid Biopsy Predict Outcomes in DLBCL?

In a study of patients with diffuse large B-cell lymphoma (DLBCL), levels of pretreatment circulating tumor DNA (ctDNA) and molecular responses were independent predictors...

U.K. Says CAR-T Cell Therapy for Non-Hodgkin Lymphoma Is Too Expensive

The U.K.’s National Institute for Health and Care Excellence (NICE) has rejected the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel for use by...
WIB_icon

Insurance Status Contributes to Survival Disparities in Follicular Lymphoma

Patients with follicular lymphoma (FL) who have private health-care insurance live longer than uninsured patients or those who are enrolled in Medicare, according to...

Ibrutinib-Rituximab Combo Granted Priority Review

The FDA granted priority-review designation to the combination of ibrutinib and rituximab for the treatment of Waldenström macroglobulinemia (WM). The Bruton tyrosine kinase inhibitor...

European Commission Approves CAR T-Cell Therapy for Two Blood Cancers

The European Commission (EC) has approved the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel for the treatment of young patients with B-cell acute lymphocytic...

FDA Approves Treatment for Two Types of NHL

The U.S. Food and Drug Administration (FDA) has approved mogamulizumab-kpkc for intravenous use in patients with relapsed or refractory mycosis fungoides (MF) or Sézary...
WIB_icon

Risk-Adapted, Chemotherapy-Alone Treatment Strategy Effective for Early-Stage Hodgkin Lymphoma

Detection of disease on interim PET/CT scans after two cycles of chemotherapy is a powerful predictor of outcomes in patients with early-stage, non-bulky Hodgkin...

Venetoclax Approved for All Patients With Relapsed/Refractory CLL and SLL

The U.S. Food and Drug Administration (FDA) granted approval to venetoclax for the treatment of patients with previously treated chronic lymphocytic leukemia (CLL) or...
Advertisement

Current Issue

October 2018, Volume 4, Issue 12

This issue features a look at the Right to Try debate, a breakdown of how epigenetics are used in hematology, and more.